(VIANEWS) – Eli Lilly and Company (LLY), Progyny (PGNY), Casella Waste Systems (CWST) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Eli Lilly and Company (LLY)
28.2% sales growth and 65.6% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $7.21.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 75.68. Meaning, the purchaser of the share is investing $75.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 65.6%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Aug 13, 2023, the estimated forward annual dividend rate is 4.52 and the estimated forward annual dividend yield is 0.82%.
2. Progyny (PGNY)
28.2% sales growth and 12.63% return on equity
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Progyny has a trailing twelve months EPS of $0.48.
PE Ratio
Progyny has a trailing twelve months price to earnings ratio of 72.25. Meaning, the purchaser of the share is investing $72.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.63%.
Volume
Today’s last reported volume for Progyny is 302766 which is 54.9% below its average volume of 671350.
Revenue Growth
Year-on-year quarterly revenue growth grew by 43.3%, now sitting on 957.46M for the twelve trailing months.
3. Casella Waste Systems (CWST)
26.4% sales growth and 5.47% return on equity
Casella Waste Systems, Inc., together with its subsidiaries, operates as a vertically integrated solid waste services company in the northeastern United States. It offers resource management services primarily in the areas of solid waste collection and disposal, transfer, recycling, and organics services to residential, commercial, municipal, and industrial customers. The company provides a range of non-hazardous solid waste services, including collections, transfer stations, and disposal facilities. It also markets recyclable metals, aluminum, plastics, and paper and corrugated cardboard that are processed at its facilities, as well as recyclables purchased from third parties. In addition, the company is involved in commodity brokerage operations. As of April 15, 2021, it owned and/or operated 46 solid waste collection operations, 58 transfer stations, 20 recycling facilities, 8 Subtitle D landfills, 4 landfill gas-to-energy facilities, and 1 landfill permitted to accept construction and demolition materials. The company was founded in 1975 and is headquartered in Rutland, Vermont.
Earnings Per Share
As for profitability, Casella Waste Systems has a trailing twelve months EPS of $0.78.
PE Ratio
Casella Waste Systems has a trailing twelve months price to earnings ratio of 99.99. Meaning, the purchaser of the share is investing $99.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.47%.
Yearly Top and Bottom Value
Casella Waste Systems’s stock is valued at $77.99 at 06:22 EST, way below its 52-week high of $95.78 and way higher than its 52-week low of $70.07.
Sales Growth
Casella Waste Systems’s sales growth is 34.9% for the ongoing quarter and 26.4% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Casella Waste Systems’s EBITDA is 4.54.
Volume
Today’s last reported volume for Casella Waste Systems is 124207 which is 58.72% below its average volume of 300936.
4. BlackRock Capital Investment Corporation (BKCC)
17.5% sales growth and 3.24% return on equity
BlackRock Capital Investment Corporation, formerly known as BlackRock Kelso Capital Corporation, is a Business Development Company specializing in investments in middle market companies. The fund invests in all industries. It prefers to invest between $10 million and $50 million and can invest more or less in companies with EBITDA or operating cash flow between $10 million and $50 million. The fund invests in the form of senior and junior secured, unsecured, and subordinated debt securities and loans including cash flow, asset backed, and junior lien facilities and equity securities. It's equity investments can be structured in the form of warrants, preferred stock, common equity co-investments, and direct investments in common stock. The fund's debt investments are principally structured to provide for current cash interest and to a lesser extent non-cash interest, particularly with subordinated debt investments, through a pay-in-kind (PIK) feature. It can also make non-control investments.
Earnings Per Share
As for profitability, BlackRock Capital Investment Corporation has a trailing twelve months EPS of $0.15.
PE Ratio
BlackRock Capital Investment Corporation has a trailing twelve months price to earnings ratio of 24.93. Meaning, the purchaser of the share is investing $24.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.24%.
Volume
Today’s last reported volume for BlackRock Capital Investment Corporation is 94615 which is 55.27% below its average volume of 211550.
5. Align Technology (ALGN)
15% sales growth and 8.68% return on equity
Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, China, and internationally. It operates in two segments, Clear Aligner; and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; and non-case products that include retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment. The Systems and Services segment offers iTero intraoral scanning system, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, and pay per scan services Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
Earnings Per Share
As for profitability, Align Technology has a trailing twelve months EPS of $4.1.
PE Ratio
Align Technology has a trailing twelve months price to earnings ratio of 75.15. Meaning, the purchaser of the share is investing $75.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.68%.
Previous days news about Align Technology(ALGN)
- According to Zacks on Tuesday, 26 September, "A couple of better-ranked stocks in the broader medical space are Align Technology (ALGN Quick QuoteALGN – Free Report) and McKesson Corporation (MCK Quick QuoteMCK – Free Report) ."
- According to Zacks on Tuesday, 26 September, "Investors interested in Medical – Dental Supplies stocks are likely familiar with Conmed (CNMD Quick QuoteCNMD – Free Report) and Align Technology (ALGN Quick QuoteALGN – Free Report) . ", "Conmed and Align Technology are both sporting a Zacks Rank of # 2 (Buy) right now. "
- Here's why you should buy align technology (algn) stock now. According to Zacks on Wednesday, 27 September, "Geographic Expansion Continues: Align Technology is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America. ", "Strong Solvency, Attractive Returns to Investors: With no debt on its balance sheet, Align Technology looks quite comfortable from the liquidity point of view. "
- According to Zacks on Wednesday, 27 September, "A couple of other top-ranked stocks in the broader medical space are Align Technology (ALGN Quick QuoteALGN – Free Report) and McKesson Corporation (MCK Quick QuoteMCK – Free Report) ."
6. MGP Ingredients (MGPI)
8.9% sales growth and 14.45% return on equity
MGP Ingredients, Inc., together with its subsidiaries, produces and supplies distilled spirits, and specialty wheat proteins and starch food ingredients. It operates through two segments, Distillery Products and Ingredient Solutions. The Distillery Products segment provides food grade alcohol for beverage applications that include bourbon and rye whiskeys, as well as grain neutral spirits, including vodka and gin; and food grade industrial alcohol, which is used as an ingredient in foods, personal care products, cleaning solutions, pharmaceuticals, and various other products. This segment also provides fuel grade alcohol for blending with gasoline; distillers feed and related co-products, such as distillers feed and corn oil; and warehouse services, including barrel put away, storage, and retrieval services, as well as blending services. The Ingredient Solutions segment provides specialty wheat starches for food applications under the Fibersym Resistant Starch, FiberRite RW Resistant Starch, Pregel Instant Starch, and Midsol Cook-up Starch names; specialty wheat proteins for food applications under the Arise and Proterra names; gluten free textured pea proteins; commodity wheat starch for food and non-food applications; and commodity wheat proteins. The company sells its products directly or through distributors to manufacturers and processors of finished packaged goods or to bakeries primarily in the United States, Japan, Thailand, Mexico, and Canada. MGP Ingredients, Inc. was founded in 1941 and is headquartered in Atchison, Kansas.
Earnings Per Share
As for profitability, MGP Ingredients has a trailing twelve months EPS of $4.91.
PE Ratio
MGP Ingredients has a trailing twelve months price to earnings ratio of 22.66. Meaning, the purchaser of the share is investing $22.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.45%.
Sales Growth
MGP Ingredients’s sales growth is 9.1% for the ongoing quarter and 8.9% for the next.
7. Allegion plc Ordinary Shares (ALLE)
5.1% sales growth and 53.7% return on equity
Allegion plc manufactures and sells mechanical and electronic security products and solutions worldwide. The company offers door closers and controls; doors and door systems; electronic security products; electronic, biometric and mobile access control systems; exit devices; locks, locksets, portable locks, and key systems; time, attendance, and workforce productivity systems; and other accessories. The company sells its products and solutions to end-users in commercial, institutional, and residential facilities, including education, healthcare, government, hospitality, commercial office, and single and multi-family residential markets under the CISA, Interflex, LCN, Schlage, SimonsVoss, and Von Duprin brands. It sells its products and solutions through distribution and retail channels, such as specialty distribution, e-commerce, and wholesalers, as well as through various retail channels comprising do-it-yourself home improvement centers, on-line and e-commerce platforms, and small specialty showroom outlets. Allegion plc was incorporated in 2013 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Allegion plc Ordinary Shares has a trailing twelve months EPS of $5.85.
PE Ratio
Allegion plc Ordinary Shares has a trailing twelve months price to earnings ratio of 17.9. Meaning, the purchaser of the share is investing $17.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 53.7%.
Sales Growth
Allegion plc Ordinary Shares’s sales growth is 4.8% for the present quarter and 5.1% for the next.
